Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
Novartis aims to help manufacture more than 50 million doses of BioNTech’s Covid-19 vaccine in 2021 at the Swiss drugmaker’s Stein, Switzerland fill-and-finish facility after the European Union’s drug regulator approved the bottling plant.
Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Switzerland-based Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.
First indications of the effectiveness of a potential vaccine against coronavirus may be available in the autumn, the head of the GAVI vaccine alliance told a Swiss newspaper, forecasting a long road from there to broad availability.
Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air.
Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.
Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology’s rollout, the government said.
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.